Kevin Jovanovic, MD
Maternal & Fetal Medicine · New York, NYNPI 1417955980
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,961 of the $9,704 with a category attached, or 61.4%. 38 manufacturers reported payments, led by KCI USA, Inc. at 39.4% of the total. Reporting peaked in 2019 at $4,819 and has fallen 87.9% since, to $586 in 2025. Among maternal & fetal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $35.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KCI USA, Inc.$4K
- AbbVie$1K
- Mayne Pharma Commercial LLC$538
- Therapeuticsmd, Inc.$496
- Agile Therapeutics, Inc.$320
- Davol Inc.$284
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$3,20033%
- Travel & lodging$4965%
- Food & beverage$5,96161%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KCI USA, Inc. | 3 | $3,820 |
| AbbVie(2 entities) | 61 | $1,400 |
| Mayne Pharma Commercial LLC | 21 | $538 |
| Therapeuticsmd, Inc. | 27 | $496 |
| Agile Therapeutics, Inc. | 23 | $320 |
| Davol Inc. | 2 | $284 |
| Millicent US Inc | 16 | $274 |
| Scynexis, Inc. | 9 | $255 |
| Avion Pharmaceuticals | 17 | $253 |
| Duchesnay USA Incorporated | 5 | $177 |
| Sumitomo Pharma America, Inc. | 7 | $158 |
| Vertical Pharmaceuticals, LLC | 8 | $157 |
| Daiichi Sankyo Inc. | 7 | $140 |
| Hologic Sales And Service, LLC | 4 | $113 |
| Evofem Biosciences, Inc. | 6 | $110 |
| Kerecis Limited | 1 | $103 |
| Biogen | 4 | $99 |
| Currax Pharmaceuticals LLC | 5 | $76 |
| Eisai Inc. | 5 | $74 |
| Lupin Inc. | 4 | $73 |
| Azurity Pharmaceuticals, Inc. | 4 | $72 |
| Merz North America, Inc. | 3 | $71 |
| Mission Pharmacal Company | 4 | $69 |
| Exeltis, USA Inc. | 4 | $67 |
| Novo Nordisk | 4 | $67 |
| Myovant Sciences Inc. | 3 | $64 |
| Acella Pharmaceuticals, LLC | 3 | $62 |
| Galderma Laboratories, L.p. | 3 | $50 |
| AMAG Pharmaceuticals, Inc. | 2 | $42 |
| Pfizer | 2 | $41 |
| Merck | 2 | $41 |
| Roche Diagnostics Corporation | 1 | $26 |
| Exact Sciences | 1 | $25 |
| Bayer | 1 | $25 |
| Smith+Nephew | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PREVENA$3,820
- Orilissa$389
- Kerecis Omega3 Marigen$309
- PROGEL$284
- ORIAHNN$146
- NEXTSTELLIS$125
- Osphena$118
- Kerecis Omega3 SurgiClose$103
- Kerecis Omega3 GraftGuide$103
How this compares
$9,704 in reported general payments places this provider in the 95th percentile of 185 maternal & fetal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 46 | $5,327 |
| DivigelEstradiol | 12 | $3,732 |
| ProgesteroneProgesterone, Micronized | 118 | $3,665 |
| Terconazole | 23 | $663 |
| ValacyclovirValacyclovir Hcl | 25 | $617 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $384 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $128 |
| Minoxidil | 15 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vertical Pharmaceuticals, LLCDivigel | $157 | $3,73212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 185 maternal & fetal medicine providers in New York.
Other maternal & fetal medicine in New York
- Heather LipkindNew York$60K
- Mary DaltonNew York$58K
- Eran BornsteinNew York$56K
- Ilan TimorNew York$36K
- Lisa NathanNew York$32K
- Russell MillerNew York$8K
- Alexander FriedmanNew York$3K
- Daniel RoshanNew York$2K
- Radoslav JovanovicNew York$2K
- Richard BerkowitzNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.